Veltro Argento — Full Portfolio
3 tracked investments · listed companies and verified rows first
BiotechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)Halley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)Ellie Hershberger(Executive Officer)
Board seatMarc Elia· per SEC Form D · $23.7M raise · filed Nov 2022
Co-investorsMithril Capital ManagementPolaris Partners
Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.
BiotechHealthtechMedical DevicesLexington, US
HARITH RAJAGOPALAN(Executive Officer, Director)JAY CAPLAN(Executive Officer, Director)Harith Rajagopalan(Executive Officer, Director)inLISA DAVIDSON(Executive Officer)Ajay Royan(Director)Christopher Gabrieli(Director)
Board seatMarc Elia· per SEC Form D · $100M raise · filed Jun 2021
Co-investorsBessemer Venture PartnersCatalio Capital Management, LPEmergent Medical Partners, LLPMithril Capital ManagementPolaris Partners
BiotechWatertown, US
Robert S. Langer, Sc.D.(Director)Armon Sharei, Ph.D.(Executive Officer, Director)Amy W. Schulman(Executive Officer, Director)Kris Elverum(Executive Officer)Howard Bernstein(Executive Officer)Klavs F. Jensen, Ph.D.(Director)
Board seatMarc Elia· per SEC Form D · $70.2M raise · filed Jun 2020
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.